Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Vivos Therapeutics (VVOS) Net Margin (2020 - 2025)

Historic Net Margin for Vivos Therapeutics (VVOS) over the last 6 years, with Q3 2025 value amounting to 79.61%.

  • Vivos Therapeutics' Net Margin fell 118400.0% to 79.61% in Q3 2025 from the same period last year, while for Sep 2025 it was 99.1%, marking a year-over-year decrease of 126200.0%. This contributed to the annual value of 74.47% for FY2024, which is 242600.0% up from last year.
  • Per Vivos Therapeutics' latest filing, its Net Margin stood at 79.61% for Q3 2025, which was down 118400.0% from 131.23% recorded in Q2 2025.
  • Vivos Therapeutics' Net Margin's 5-year high stood at 44.15% during Q1 2023, with a 5-year trough of 168.25% in Q4 2021.
  • For the 5-year period, Vivos Therapeutics' Net Margin averaged around 111.45%, with its median value being 119.95% (2021).
  • As far as peak fluctuations go, Vivos Therapeutics' Net Margin soared by 1774300bps in 2021, and later tumbled by -836200bps in 2025.
  • Vivos Therapeutics' Net Margin (Quarter) stood at 168.25% in 2021, then rose by 8bps to 154.15% in 2022, then increased by 14bps to 132.45% in 2023, then surged by 41bps to 78.02% in 2024, then fell by -2bps to 79.61% in 2025.
  • Its last three reported values are 79.61% in Q3 2025, 131.23% for Q2 2025, and 128.12% during Q1 2025.